Customer Service 1 (888) 261-2693
Advanced Search

The Flip Side of Drug Disasters

By Rob Fannon, editor Phase 1 Investor
Friday, June 8, 2007

In 1996, a drug company called American Home Products (AHP) was on top of the world...
 
It had just launched a highly anticipated new diet drug, called Redux (chemical name: dexfenfluramine), and sales were soaring. Doctors were prescribing the drug at unprecedented levels – more than 20 million prescriptions were written in the first year.
 
Redux was prescribed alongside another popular diet drug on the market – phentermine. The two drugs, taken together, were helping patients shed unwanted pounds at unheard-of rates.
 
The popular drug combination came to be known as "fen-phen."
 
The AHP drug, the "fen" portion of the combo, became the main culprit behind one of the worst drug disasters in modern history...
 
Once hailed as the first-in-class breakthrough obesity drug, it was pulled off the market in 1997, only one year after its launch. A study by the Mayo Clinic reported defects in the heart valves of two dozen women taking fen-phen. Since then, 66 studies with similar findings have been reported to the FDA. Current estimates claim approximately 30% of the 6 million Americans who used the drug during its brief stint on the market may be at risk.
 
The problem was that the AHP scientists didn't predict how "well" Redux actually worked. It targeted a particular family of receptors in the brain that regulate appetite and satiety (the feeling of being full). However, in addition to these receptors, the drug had an unusually high affect on similar receptors in the heart.
 
This is what led to the safety debacle. The medicine got ahead of the science.
 
In 2002, American Home Products changed its name. Today, American Home Products is known as Wyeth (WYE) – a $64 billion, Fortune 500 pharmaceutical company.
 
Wyeth is still sorting out the fen-phen nightmare; it has set aside $21 billion to cover the expenses and damages from the 50,000 lawsuits that have been filed.
 
In the years since the fen-phen fallout, the science behind the deadly mess has become much clearer. The problematic receptor in the heart has been identified.
 
And here's where investors can make a fortune... huge gains in biotech aren't made with initial scientific discoveries. High returns are won when medicine and cutting-edge science align – meaning the science is so well understood that it can be applied to humans, not just lab rats.
 
Right now, the second-generation obesity drug that works as the original "fen" drug was intended, without the side effects, is sailing through clinical trials – and the company developing the drug is one of Phase 1 Investor's top performers. Readers are up about 50% in a little less than a year. Yet, there's one critical piece of safety data due this summer that could provide readers another 50% bump practically overnight.
 
If the safety data looks clean – and I expect it will – this drug will be a very hot commodity... essentially, a must-have by Big Pharma. The company will get very favorable offers for partnership (or even a buyout). Either way, shareholders should make huge gains.
 
The company continues to hover around my recommended buy price. As I told readers last month, I believe it "should be at the core of every biotech portfolio."
 
Good investing,
 
Rob Fannon




Recent Articles
Market Notes
Shoemaker Crocs hits new all-time high. Now trading at 43 times earnings.
 
Starbucks at a fresh new 52-week low.
 
The sacred cows of tech reach new highs... Google, Amazon, and Apple.
 
New all-time high for BHP Billiton, world's largest miner. Up 39% this year.
Market Watch
Symbol Price
Change
52-Wk
S&P 500 1221.53 +1.3% +10.1%
Oil 38.31 +1.4% -0.6%
Gold 138.07 +2.1% +16.3%
Silver 28.60 +2.4% +53.6%
US-Dollar 80.67 -0.8% +8.1%
Euro 1.32 +0.6% -12.1%
Volatility 18.01 -7.1% -19.8%
Gold Stocks 581.56 +3.0% +17.0%
10-Year Yield 3.02 +0.7% -10.7%

World ETFs
Symbol Price
Change
52-Wk
USA 122.89 +0.3% +11.3%
Canada 30.50 +0.2% +16.2%
Russia 21.94 +1.4% +18.1%
India 37.85 +0.3% +22.3%
Israel 16.69 +1.3% +10.8%
Japan 10.64 +0.6% +6.5%
Singapore 13.73 -1.1% +18.8%
Taiwan 14.78 +0.4% +19.2%
S. Korea 57.31 +1.3% +23.4%
S. Africa 71.87 +1.4% +28.2%
China 44.42 -1.4% -0.6%
Lat.America 53.17 +0.7% +8.4%

Sector ETFs
Symbol Price
Change
52-Wk
Oil Service 137.59 +1.0% +18.9%
Big Pharma 64.14 +0.0% -3.2%
Internet 72.07 -0.1% +23.4%
Semis 16.22 +1.2% +29.4%
Utilities 31.28 +0.2% +1.5%
Defense 18.52 +0.1% +10.6%
Nanotech 10.03 +0.4% +1.6%
Alt. Energy 10.08 +1.3% -3.3%
Water 18.49 +1.0% +14.5%
Insurance 16.14 +0.4% +21.1%
Biotech 20.54 -0.2% +28.1%
Retail 19.70 +0.3% +30.2%
Software 24.79 +0.8% +25.9%
Big Tech 53.87 +0.3% +22.7%
Construction 13.10 +0.9% +15.7%
Media 13.64 +0.5% +26.0%
Consumer Svcs 67.39 +0.2% +24.5%
Financials 55.04 +0.3% +7.4%
Health Care 64.30 +0.1% +2.0%
Industrials 63.54 +0.5% +21.0%
Basic Mat 74.35 +1.1% +25.3%
Real Estate 55.32 +0.1% +25.0%
Transportation 91.77 +0.7% +26.9%
Telecom 22.59 +0.5% +17.8%